Skip to main content
Erschienen in: World Journal of Surgery 8/2015

01.08.2015 | Original Scientific Report

Clinicopathological Meaning of Size of Main-Duct Dilatation in Intraductal Papillary Mucinous Neoplasm of Pancreas: Proposal of a Simplified Morphological Classification Based on the Investigation on the Size of Main Pancreatic Duct

verfasst von: Mee Joo Kang, Jin-Young Jang, Selyeong Lee, Taesung Park, Seung Yeoun Lee, Sun-Whe Kim

Erschienen in: World Journal of Surgery | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

The 2012 consensus guideline on intraductal papillary mucinous neoplasm of the pancreas (IPMN) described a three-stage criteria involving main pancreatic duct (MPD) size with definitions of malignancy relevant for treatment decisions. Re-evaluation and simplification of this classification for clinicians are warranted.

Methods

Data from the Seoul National University Hospital of 375 consecutive patients with pathology-confirmed IPMN after surgery were analyzed. The association between clinicopathologic characteristics of IPMN and MPD size was assessed. The cut-off value of MPD size for a current definition of malignancy prediction was calculated.

Results

Diagnostic accuracy for malignancy was highest when the cut-off value of MPD size was 7 mm (area under the curve = 0.7126). Dichotomizing IPMN into MPD ≤7 mm versus MPD >7 mm, patient age (p = 0.039), sex (p = 0.001), presence of mural nodule (p < 0.001), and invasiveness risk (13.2 vs. 39.8 %, p < 0.001) resulted in significantly different results. Mural nodule-negative patients with MPD >7 mm had a significantly lower 5-year survival rate than those with MPD ≤7 mm (78.4 vs. 91.4 %, p = 0.006). Among patients with MPD size ≤7 mm, elevated serum CA 19-9 and mural nodule were independent risk factors of malignancy. Patients with MPD size ≤7 mm without these risk factors had malignancy risk of 2.6 %.

Conclusion

Using the definition of malignancy provided in the 2012 guideline, the MPD size >7 mm criterion was statistically driven. The current morphologic classification of IPMN can be simplified as branch-duct-predominant IPMN (MPD ≤7 mm)’ and main-duct-predominant IPMN (MPD >7 mm). Patients who are determined to have main-duct-predominant IPMN and branch-duct-predominant IPMN with elevated serum CA 19-9 or mural nodule are recommended to undergo surgical treatment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Tanaka M, Chari S, Adsay V et al (2006) International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6:17–32PubMedCrossRef Tanaka M, Chari S, Adsay V et al (2006) International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6:17–32PubMedCrossRef
2.
Zurück zum Zitat Tanaka M, Fernandez-Del Castillo C, Adsay V et al (2012) International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12:183–197PubMedCrossRef Tanaka M, Fernandez-Del Castillo C, Adsay V et al (2012) International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12:183–197PubMedCrossRef
3.
Zurück zum Zitat Salvia R, Fernández-del Castillo C, Bassi C et al (2004) Main-duct intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 239:678–687PubMedCentralPubMedCrossRef Salvia R, Fernández-del Castillo C, Bassi C et al (2004) Main-duct intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 239:678–687PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Shimizu Y, Yamaue H, Maguchi H et al (2013) Predictors of malignancy in intraductal papillary mucinous neoplasm of the pancreas: analysis of 310 pancreatic resection patients at multiple high-volume centers. Pancreas 42:883–888PubMedCrossRef Shimizu Y, Yamaue H, Maguchi H et al (2013) Predictors of malignancy in intraductal papillary mucinous neoplasm of the pancreas: analysis of 310 pancreatic resection patients at multiple high-volume centers. Pancreas 42:883–888PubMedCrossRef
5.
Zurück zum Zitat Anand N, Sampath K, Wu BU (2013) Cyst features and risk of malignancy in intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis. Clin Gastroenterol Hepatol 11:913–921PubMedCrossRef Anand N, Sampath K, Wu BU (2013) Cyst features and risk of malignancy in intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis. Clin Gastroenterol Hepatol 11:913–921PubMedCrossRef
6.
Zurück zum Zitat Kawamoto S, Lawler LP, Horton KM et al (2006) MDCT of intraductal papillary mucinous neoplasm of the pancreas: evaluation of features predictive of invasive carcinoma. AJR Am J Roentgenol 186:687–695PubMedCrossRef Kawamoto S, Lawler LP, Horton KM et al (2006) MDCT of intraductal papillary mucinous neoplasm of the pancreas: evaluation of features predictive of invasive carcinoma. AJR Am J Roentgenol 186:687–695PubMedCrossRef
7.
Zurück zum Zitat Bournet B, Kirzin S, Carrere N et al (2009) Clinical fate of branch duct and mixed forms of intraductal papillary mucinous neoplasia of the pancreas. J Gastroenterol Hepatol 24:1211–1217PubMedCrossRef Bournet B, Kirzin S, Carrere N et al (2009) Clinical fate of branch duct and mixed forms of intraductal papillary mucinous neoplasia of the pancreas. J Gastroenterol Hepatol 24:1211–1217PubMedCrossRef
8.
Zurück zum Zitat Sahani DV, Kadavigere R, Blake M et al (2006) Intraductal papillary mucinous neoplasm of pancreas: multi-detector row CT with 2D curved reformations—correlation with MRCP. Radiology 238:560–569PubMedCrossRef Sahani DV, Kadavigere R, Blake M et al (2006) Intraductal papillary mucinous neoplasm of pancreas: multi-detector row CT with 2D curved reformations—correlation with MRCP. Radiology 238:560–569PubMedCrossRef
9.
Zurück zum Zitat Akita H, Takeda Y, Hoshino H et al (2011) Mural nodule in branch duct-type intraductal papillary mucinous neoplasms of the pancreas is a marker of malignant transformation and indication for surgery. Am J Surg 202:214–219PubMedCrossRef Akita H, Takeda Y, Hoshino H et al (2011) Mural nodule in branch duct-type intraductal papillary mucinous neoplasms of the pancreas is a marker of malignant transformation and indication for surgery. Am J Surg 202:214–219PubMedCrossRef
10.
Zurück zum Zitat Schmidt CM, White PB, Waters JA et al (2007) Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg 246:644–651; discussion 651–644PubMedCrossRef Schmidt CM, White PB, Waters JA et al (2007) Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg 246:644–651; discussion 651–644PubMedCrossRef
11.
Zurück zum Zitat Waters JA, Schmidt CM, Pinchot JW et al (2008) CT vs MRCP: optimal classification of IPMN type and extent. J Gastrointest Surg 12:101–109PubMedCrossRef Waters JA, Schmidt CM, Pinchot JW et al (2008) CT vs MRCP: optimal classification of IPMN type and extent. J Gastrointest Surg 12:101–109PubMedCrossRef
12.
Zurück zum Zitat Kang MJ, Jang JY, Kim SJ et al (2011) Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol 9:87–93PubMedCrossRef Kang MJ, Jang JY, Kim SJ et al (2011) Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol 9:87–93PubMedCrossRef
13.
Zurück zum Zitat Hwang DW, Jang JY, Lee SE et al (2012) Clinicopathologic analysis of surgically proven intraductal papillary mucinous neoplasms of the pancreas in SNUH: a 15-year experience at a single academic institution. Langenbecks Arch Surg 397:93–102PubMedCrossRef Hwang DW, Jang JY, Lee SE et al (2012) Clinicopathologic analysis of surgically proven intraductal papillary mucinous neoplasms of the pancreas in SNUH: a 15-year experience at a single academic institution. Langenbecks Arch Surg 397:93–102PubMedCrossRef
14.
Zurück zum Zitat Sadakari Y, Ienaga J, Kobayashi K et al (2010) Cyst size indicates malignant transformation in branch duct intraductal papillary mucinous neoplasm of the pancreas without mural nodules. Pancreas 39:232–236PubMedCrossRef Sadakari Y, Ienaga J, Kobayashi K et al (2010) Cyst size indicates malignant transformation in branch duct intraductal papillary mucinous neoplasm of the pancreas without mural nodules. Pancreas 39:232–236PubMedCrossRef
15.
Zurück zum Zitat Lee CJ, Scheiman J, Anderson MA et al (2008) Risk of malignancy in resected cystic tumors of the pancreas ≤3 cm in size: is it safe to observe asymptomatic patients? A multi-institutional report. J Gastrointest Surg 12:234–242PubMedCrossRef Lee CJ, Scheiman J, Anderson MA et al (2008) Risk of malignancy in resected cystic tumors of the pancreas ≤3 cm in size: is it safe to observe asymptomatic patients? A multi-institutional report. J Gastrointest Surg 12:234–242PubMedCrossRef
16.
Zurück zum Zitat Irie H, Honda H, Aibe H et al (2000) MR cholangiopancreatographic differentiation of benign and malignant intraductal mucin-producing tumors of the pancreas. AJR Am J Roentgenol 174:1403–1408PubMedCrossRef Irie H, Honda H, Aibe H et al (2000) MR cholangiopancreatographic differentiation of benign and malignant intraductal mucin-producing tumors of the pancreas. AJR Am J Roentgenol 174:1403–1408PubMedCrossRef
17.
Zurück zum Zitat Nakagohri T, Kinoshita T, Konishi M et al (2007) Surgical outcome of intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol 14:3174–3180PubMedCrossRef Nakagohri T, Kinoshita T, Konishi M et al (2007) Surgical outcome of intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol 14:3174–3180PubMedCrossRef
18.
Zurück zum Zitat Mimura T, Masuda A, Matsumoto I et al (2010) Predictors of malignant intraductal papillary mucinous neoplasm of the pancreas. J Clin Gastroenterol 44:e224–e229PubMedCrossRef Mimura T, Masuda A, Matsumoto I et al (2010) Predictors of malignant intraductal papillary mucinous neoplasm of the pancreas. J Clin Gastroenterol 44:e224–e229PubMedCrossRef
19.
Zurück zum Zitat Sugiyama M, Izumisato Y, Abe N et al (2003) Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J Surg 90:1244–1249PubMedCrossRef Sugiyama M, Izumisato Y, Abe N et al (2003) Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J Surg 90:1244–1249PubMedCrossRef
20.
Zurück zum Zitat Nara S, Onaya H, Hiraoka N et al (2009) Preoperative evaluation of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas: clinical, radiological, and pathological analysis of 123 cases. Pancreas 38:8–16PubMedCrossRef Nara S, Onaya H, Hiraoka N et al (2009) Preoperative evaluation of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas: clinical, radiological, and pathological analysis of 123 cases. Pancreas 38:8–16PubMedCrossRef
21.
Zurück zum Zitat Nagai K, Doi R, Doi R, Ito T et al (2009) Single-institution validation of the international consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas. J Hepatobiliary Pancreat Surg 16:353–358PubMedCrossRef Nagai K, Doi R, Doi R, Ito T et al (2009) Single-institution validation of the international consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas. J Hepatobiliary Pancreat Surg 16:353–358PubMedCrossRef
22.
Zurück zum Zitat Kim SC, Park KT, Lee YJ et al (2008) Intraductal papillary mucinous neoplasm of the pancreas: clinical characteristics and treatment outcomes of 118 consecutive patients from a single center. J Hepatobiliary Pancreat Surg 15:183–188PubMedCrossRef Kim SC, Park KT, Lee YJ et al (2008) Intraductal papillary mucinous neoplasm of the pancreas: clinical characteristics and treatment outcomes of 118 consecutive patients from a single center. J Hepatobiliary Pancreat Surg 15:183–188PubMedCrossRef
23.
Zurück zum Zitat Adsay NV, Kloppel G, Fukushima N et al (2010) Intraductal neoplasms of the pancreas. In: Bosman FT, Carneiro F, Hruban RH (eds) WHO classification of tumours of the digestive system. IARC Press, Lyon Adsay NV, Kloppel G, Fukushima N et al (2010) Intraductal neoplasms of the pancreas. In: Bosman FT, Carneiro F, Hruban RH (eds) WHO classification of tumours of the digestive system. IARC Press, Lyon
24.
Zurück zum Zitat Ohno E, Hirooka Y, Itoh A et al (2009) Intraductal papillary mucinous neoplasms of the pancreas: differentiation of malignant and benign tumors by endoscopic ultrasonography findings of mural nodules. Ann Surg 249:628–634PubMedCrossRef Ohno E, Hirooka Y, Itoh A et al (2009) Intraductal papillary mucinous neoplasms of the pancreas: differentiation of malignant and benign tumors by endoscopic ultrasonography findings of mural nodules. Ann Surg 249:628–634PubMedCrossRef
25.
Zurück zum Zitat Einstein DM, Singer AA, Chilcote WA et al (1991) Abdominal lymphadenopathy: spectrum of CT findings. Radiographics 11:457–472PubMedCrossRef Einstein DM, Singer AA, Chilcote WA et al (1991) Abdominal lymphadenopathy: spectrum of CT findings. Radiographics 11:457–472PubMedCrossRef
26.
Zurück zum Zitat Arikawa S, Uchida M, Uozumi J et al (2011) Utility of multidetector row CT in diagnosing branch duct IPMNs of the pancreas compared with MR cholangiopancreatography and endoscopic ultrasonography. Kurume Med J 57:91–100PubMedCrossRef Arikawa S, Uchida M, Uozumi J et al (2011) Utility of multidetector row CT in diagnosing branch duct IPMNs of the pancreas compared with MR cholangiopancreatography and endoscopic ultrasonography. Kurume Med J 57:91–100PubMedCrossRef
27.
Zurück zum Zitat Serikawa M, Sasaki T, Fujimoto Y et al (2006) Management of intraductal papillary-mucinous neoplasm of the pancreas: treatment strategy based on morphologic classification. J Clin Gastroenterol 40:856–862PubMedCrossRef Serikawa M, Sasaki T, Fujimoto Y et al (2006) Management of intraductal papillary-mucinous neoplasm of the pancreas: treatment strategy based on morphologic classification. J Clin Gastroenterol 40:856–862PubMedCrossRef
28.
Zurück zum Zitat Levy P, Jouannaud V, O’Toole D et al (2006) Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy. Clin Gastroenterol Hepatol 4:460–468PubMedCrossRef Levy P, Jouannaud V, O’Toole D et al (2006) Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy. Clin Gastroenterol Hepatol 4:460–468PubMedCrossRef
29.
Zurück zum Zitat Crippa S, Fernandez-Del Castillo C, Salvia R et al (2010) Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol 8:213–219PubMedCentralPubMedCrossRef Crippa S, Fernandez-Del Castillo C, Salvia R et al (2010) Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol 8:213–219PubMedCentralPubMedCrossRef
30.
Zurück zum Zitat Takano S, Fukasawa M, Maekawa S et al (2014) Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation. PLoS ONE 9:e98718PubMedCentralPubMedCrossRef Takano S, Fukasawa M, Maekawa S et al (2014) Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation. PLoS ONE 9:e98718PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Dal Molin M, Matthaei H, Wu J et al (2013) Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg Oncol 20:3802–3808PubMedCrossRef Dal Molin M, Matthaei H, Wu J et al (2013) Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg Oncol 20:3802–3808PubMedCrossRef
32.
Zurück zum Zitat He J, Cameron JL, Ahuja N et al (2013) Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? J Am Coll Surg 216:657–665; discussion 665–657PubMedCentralPubMedCrossRef He J, Cameron JL, Ahuja N et al (2013) Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? J Am Coll Surg 216:657–665; discussion 665–657PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Kang MJ, Jang JY, Lee KB et al (2013) Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance. Ann Surg 260:356–363CrossRef Kang MJ, Jang JY, Lee KB et al (2013) Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance. Ann Surg 260:356–363CrossRef
Metadaten
Titel
Clinicopathological Meaning of Size of Main-Duct Dilatation in Intraductal Papillary Mucinous Neoplasm of Pancreas: Proposal of a Simplified Morphological Classification Based on the Investigation on the Size of Main Pancreatic Duct
verfasst von
Mee Joo Kang
Jin-Young Jang
Selyeong Lee
Taesung Park
Seung Yeoun Lee
Sun-Whe Kim
Publikationsdatum
01.08.2015
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 8/2015
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-015-3062-0

Weitere Artikel der Ausgabe 8/2015

World Journal of Surgery 8/2015 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.